Invivyd, Inc. (IVVD)
| Market Cap | 218.27M +156.9% |
| Revenue (ttm) | 58.37M +26.3% |
| Net Income | -107.33M |
| EPS | -0.40 |
| Shares Out | 294.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,765,230 |
| Open | 0.7100 |
| Previous Close | 0.7209 |
| Day's Range | 0.6820 - 0.7499 |
| 52-Week Range | 0.4830 - 3.0700 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+1,250.44%) |
| Earnings Date | Aug 13, 2026 |
About IVVD
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatmen... [Read more]
Financial Performance
In 2025, Invivyd's revenue was $53.43 million, an increase of 110.47% compared to the previous year's $25.38 million. Losses were -$52.49 million, -69.11% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 1,250.44% from the latest price.
News
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.
Invivyd Earnings release: Q2 2026
Invivyd released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Invivyd Quarterly report: Q2 2026
Invivyd has published its Q2 2026 quarterly earnings report on August 13, 2026.
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an ...
Invivyd announces notice of termination for Pemgarda Emergency Use Authorization
Invivyd (IVVD) announced that the FDA has sent Invivyd a notice of termination for the Pemgarda Emergency Use Authorization, or EUA, following the U.S. Department of Health and Human Services’,…
Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
NEW HAVEN, Conn., July 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has sent Invivyd a Notice of Termination for the PEMGA...
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an agg...
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for ar...
Invivyd completes enrollment of LIBERTY clinical trial
Invivyd (IVVD) announced enrollment of participants in its Phase 3 LIBERTY clinical trial is complete. The trial is comparing the safety and tolerability of the company’s investigational COVID-19 mono...
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
NEW HAVEN, Conn., June 16, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced enrollment of participants in its Phase 3 LIBERTY clinical trial is complete. The trial is comparing th...
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
NEW HAVEN, Conn., June 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the first participants have been dosed in the LIBERTY Phase 3 clinical trial, a randomized, double...
Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series
The conference highlighted a robust pipeline of monoclonal antibodies for infectious diseases, with VYD2311 in late-stage development targeting broad COVID-19 prophylaxis. Key programs in RSV, measles, and long COVID are advancing, with commercial and regulatory strategies focused on broadening access and market impact.
Invivyd Transcript: Jefferies Global Healthcare Conference 2026
Monoclonal antibodies are positioned as a disruptive, more natural alternative or complement to vaccines, with pivotal COVID-19 trial data expected in late Q3. The pipeline targets RSV and measles, aiming to improve outcomes for vulnerable populations and reshape public health strategies.
Invivyd completes enrollment in DECLARATION trial
Invivyd (IVVD) announced the completion of enrollment in the DECLARATION trial evaluating VYD2311, an investigational monoclonal antibody candidate for the prevention of symptomatic COVID-19. DECLARAT...
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
NEW HAVEN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the completion of enrollment in the DECLARATION trial evaluating VYD2311, an investigational monoclonal...
Invivyd to Participate in Upcoming Investor Events
NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:
Invivyd management to meet with BTIG
Biotechnology Analyst Shrader holds a group dinner meeting in Greenwich, CT on May 21 at 6 pm hosted by BTIG.
Invivyd Transcript: AGM 2026
The meeting confirmed a quorum, elected six directors for one-year terms, and ratified the independent auditor for 2026. No additional proposals or questions were raised, and forward-looking statements referenced risk factors in the annual report.
Invivyd post earnings selloff overdone, says H.C. Wainwright
H.C. Wainwright attributes the post-earnings selloff in shares of Invivyd (IVVD) to the Q1 revenue miss and its higher than expected research and development expense of $30.7M. The selloff is…
Invivyd Earnings Call Transcript: Q1 2026
VYD2311 pivotal trial is progressing well, with strong PEMGARDA sales and a robust cash position. The company is expanding its antibody pipeline and preparing for potential VYD2311 commercialization, while leveraging AI and public education to drive growth.
Invivyd Earnings release: Q1 2026
Invivyd released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Invivyd Slides: Q1 2026
Invivyd has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Invivyd Quarterly report: Q1 2026
Invivyd has published its Q1 2026 quarterly earnings report on May 14, 2026.
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutral...
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues Results allow for compar...